BSE:500680

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. More Details

Rewards

Earnings grew by 15.6% over the past year

Risk Analysis

No risks detected for 500680 from our risk checks.


Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Pfizer's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 500680 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.8%

500680

-1.7%

IN Pharmaceuticals

-0.6%

IN Market


1 Year Return

30.7%

500680

45.4%

IN Pharmaceuticals

0.9%

IN Market

Return vs Industry: 500680 underperformed the Indian Pharmaceuticals industry which returned 45.4% over the past year.

Return vs Market: 500680 exceeded the Indian Market which returned 0.9% over the past year.


Shareholder returns

500680IndustryMarket
7 Day2.8%-1.7%-0.6%
30 Day4.5%-0.8%4.0%
90 Day19.5%11.7%5.7%
1 Year40.0%30.7%47.2%45.4%2.6%0.9%
3 Year221.8%196.6%22.6%19.3%-2.8%-7.4%
5 Year121.4%100.1%-0.2%-3.7%39.9%29.5%

Price Volatility Vs. Market

How volatile is Pfizer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pfizer undervalued compared to its fair value and its price relative to the market?

45.14x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 500680 (₹5137.8) is trading above our estimate of fair value (₹968.52)

Significantly Below Fair Value: 500680 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500680 is poor value based on its PE Ratio (45.1x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: 500680 is poor value based on its PE Ratio (45.1x) compared to the Indian market (16.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500680's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 500680 is overvalued based on its PB Ratio (6.9x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pfizer has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Pfizer performed over the past 5 years?

22.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500680 has high quality earnings.

Growing Profit Margin: 500680's current net profit margins (24.5%) are higher than last year (21.3%).


Past Earnings Growth Analysis

Earnings Trend: 500680's earnings have grown significantly by 22.4% per year over the past 5 years.

Accelerating Growth: 500680's earnings growth over the past year (15.6%) is below its 5-year average (22.4% per year).

Earnings vs Industry: 500680 earnings growth over the past year (15.6%) exceeded the Pharmaceuticals industry 14.7%.


Return on Equity

High ROE: 500680's Return on Equity (15.3%) is considered low.


Next Steps

Financial Health

How is Pfizer's financial position?


Financial Position Analysis

Short Term Liabilities: 500680's short term assets (₹30.5B) exceed its short term liabilities (₹8.7B).

Long Term Liabilities: 500680's short term assets (₹30.5B) exceed its long term liabilities (₹1.4B).


Debt to Equity History and Analysis

Debt Level: 500680 is debt free.

Reducing Debt: 500680 has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.

Debt Coverage: 500680 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 500680 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Pfizer current dividend yield, its reliability and sustainability?

0.19%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 500680's dividend (0.19%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.56%).

High Dividend: 500680's dividend (0.19%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).


Stability and Growth of Payments

Stable Dividend: 500680 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: 500680 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 500680 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 500680's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average management tenure


CEO

Sridhar Subramaniam (52 yo)

4.58yrs

Tenure

₹41,060,597

Compensation

Mr. Sridhar Subramaniam has been the Chief Executive Officer, Managing Director & Lead – Essential Health Portfolio of Pfizer Limited since March 18, 2016. He served as Business Unit Head of Pfizer Limited ...


CEO Compensation Analysis

Compensation vs Market: Sridhar's total compensation ($USD555.35K) is about average for companies of similar size in the Indian market ($USD775.42K).

Compensation vs Earnings: Sridhar's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Sridhar Subramaniam
CEO, MD4.58yrs₹41.06mno data
Milind Patil
CFO, Executive Director of Finance & Executive Director1.92yrs₹21.04mno data
Prajeet Nair
Compliance Officer & Company Secretary13.08yrs₹5.22m0%
₹ 0
Samir Kazi
Executive Director & Executive Director of Legal0.67yr₹11.67mno data
Sharad Goswami
Senior Director of Public Affairsno datano datano data
Shilpi Singh
Director of Human Resourcesno datano datano data

7.7yrs

Average Tenure

52yo

Average Age

Experienced Management: 500680's management team is seasoned and experienced (7.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sridhar Subramaniam
CEO, MD4.58yrs₹41.06mno data
Milind Patil
CFO, Executive Director of Finance & Executive Director1.92yrs₹21.04mno data
Samir Kazi
Executive Director & Executive Director of Legal0.67yr₹11.67mno data
Meena Ganesh
Additional Independent Director1.58yrs₹1.76mno data
Rajendra Shah
Non Executive Independent Chairmanno data₹1.99m0.0077%
₹ 18.4m
Sunil Lalbhai
Non Executive Independent Director5.67yrs₹1.79m0.0054%
₹ 12.8m
Pradip Shah
Non-Executive Independent Director20.83yrs₹2.08mno data
Uday Khanna
Non Executive Independent Director8.42yrs₹2.02mno data
Susan Desmond-Hellmann
Director0.75yrno datano data

3.8yrs

Average Tenure

60yo

Average Age

Experienced Board: 500680's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pfizer Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pfizer Limited
  • Ticker: 500680
  • Exchange: BSE
  • Founded: 1950
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹237.351b
  • Shares outstanding: 45.75m
  • Website: https://www.pfizerindia.com

Number of Employees


Location

  • Pfizer Limited
  • The Capital
  • 1802 / 1901, 18th Floor
  • Mumbai
  • Maharashtra
  • 400051
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500680BSE (Mumbai Stock Exchange)YesEquity SharesININRMar 1999
PFIZERNSEI (National Stock Exchange of India)YesEquity SharesININRMar 1999

Biography

Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. It offers its various products in various therapeutic areas, including anti-allergic, anti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 12:59
End of Day Share Price2020/10/27 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.